FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
This article was originally published in The Tan Sheet
Executive Summary
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
You may also be interested in...
Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles
Pfizer would face major hurdles in research on consumers’ safe self-selection for FDA to approve an OTC switch of the firm’s cholesterol treatment Lipitor.
CDER Director Sees Behind-The-Counter Switches As Best Bet
FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.
OTC Switch Pathway Abroad Looks Smoother, But Payoffs Are Lower
Switching new Rx drug categories to OTC abroad may appeal to firms put off by the trickle of switches in the U.S., but the payoff abroad is smaller and there is no guarantee FDA will follow another government's decision, experts say